Title |
Flupirtine, a re-discovered drug, revisited
|
---|---|
Published in |
Inflammation Research, January 2013
|
DOI | 10.1007/s00011-013-0592-5 |
Pubmed ID | |
Authors |
Istvan Szelenyi |
Abstract |
Flupirtine was developed long before K(V)7 (KCNQ) channels were known. However, it was clear from the beginning that flupirtine is neither an opioid nor a nonsteroidal anti-inflammatory analgesic. Its unique muscle relaxing activity was discovered by serendipity. In the meantime, broad and intensive research has resulted in a partial clarification of its mode of action. Flupirtine is the first therapeutically used K(V)7 channel activator with additional GABA(A)ergic mechanisms and thus the first representative of a novel class of analgesics. The presently accepted main mode of its action, potassium K(V)7 (KCNQ) channel activation, opens a series of further therapeutic possibilities. One of them has now been realized: its back-up compound, the bioisostere retigabine, has been approved for the treatment of epilepsy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Unknown | 52 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 13 | 25% |
Other | 7 | 13% |
Professor | 4 | 8% |
Student > Bachelor | 3 | 6% |
Student > Doctoral Student | 3 | 6% |
Other | 9 | 17% |
Unknown | 14 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 21% |
Agricultural and Biological Sciences | 9 | 17% |
Chemistry | 5 | 9% |
Neuroscience | 5 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Other | 6 | 11% |
Unknown | 14 | 26% |